Form 4: Verona Pharma Director Exercises Options and Disposes of Shares

Sentiment:

SEC Form 4


Director David R. Ebsworth exercised share options and disposed of ordinary shares of Verona Pharma plc on February 26, 2025.

Summary

  • On February 26, 2025, David R. Ebsworth, a director of Verona Pharma plc, exercised share options to acquire a total of 460,000 ordinary shares.
  • These options were exercised at prices of $0.775, $0.5038, $2.67, and $1.9338 per share.
  • Following these transactions, Ebsworth directly owns 1,336,003 ordinary shares and 140,000 share options.
  • A portion of the shares were disposed of at $0.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions, which is neutral in sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.

Stakeholder Impact

  • The transactions may have a minor impact on shareholders due to the change in ownership structure.

Key Dates

DateDescription
07/29/202425% of 100,000 options vest and become exercisable
10/29/202425% of 100,000 options vest and become exercisable
01/29/202525% of 100,000 options vest and become exercisable
02/26/2025Date of transaction: exercise of share options and disposal of shares
04/27/2032Expiration date for share options
04/27/2033Expiration date for share options
04/28/2034Expiration date for share options
02/28/2025Date of signature

Keywords

Verona Pharma, Director, Ebsworth, Share Options, Ordinary Shares, Beneficial Ownership, Form 4, VRNA

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.